There is no indication that the U.S. is going to have a recession in 2012, says Howard Ward, Gamco Growth Fund, who breaks down earnings seasons with Charlie Smith, Fort Pitt Capital Group. Smith says there is some weakness short-cycle businesses who a...
How did Facebook become worth so much money that it could?file for the biggest IPO in tech history? By building?a highly defensible product, platform, and advertising business on top of brilliant talent and valuable data. It now has several competitive?advantages?that protect it from disruption and could give it a long life as the primary online identity provider. Here are the 5 components that make Facebook a smart long-term bet for investors, regardless of its exact IPO pricing.
Filling R&D gaps key to succeeding in NTD control and elimination goals by 2020Public release date: 30-Jan-2012 [ | E-mail | Share ]
Contact: Violaine Dallenbach vdallenbach@dndi.org 41-794-241-474 Drugs for Neglected Diseases Initiative
Geneva & London On the occasion of today's high-level event in London, 'Uniting to Combat Neglected Tropical Diseases,' organized in support of the new World Health Organization (WHO) Neglected Tropical Disease (NTD) 2020 Roadmap, the Drugs for Neglected Diseases initiative (DNDi) welcomes the commitments from various partners and emphasizes that filling the major gaps in research and development (R&D) for new treatment and diagnostic tools is key to effectively support elimination or control of targeted NTDs by 2020.
Since its inception in 2003, DNDi, a not-for-profit R&D organization, has worked to develop and deliver new drugs for NTDs, in particular those with the highest mortality rates: human African trypanosomiasis (sleeping sickness), Chagas disease, and visceral leishmaniasis (kala azar). DNDi was created to address the market and public-policy failures that had led to a virtual standstill in R&D for new drugs to treat neglected diseases. Working collaboratively with public and private partners worldwide, DNDi has developed six new treatments for neglected patients, with several new drug candidates in the R&D pipeline, including two for sleeping sickness (fexinidazole, oxaborole/SCYX-7158) and one for Chagas (E1224) in clinical trials.
'For some NTDs, especially those with the highest death rates such as sleeping sickness, Chagas disease, and visceral leishmaniasis, disease control or elimination will only be achievable with further commitments to R&D,' says Dr Bernard Pcoul, Executive Director of DNDi. 'New drugs and diagnostics are urgently needed to improve patient care, respond to the challenge of drug resistance, and enhance prospects for achieving disease elimination.'
In the case of sleeping sickness, which continues to kill in remote or unstable pockets of sub-Saharan Africa, diagnostic tools are inadequate (painful lumbar punctures must be performed), and while nifurtimox-eflornithine combination therapy is an improved option therapy, it still requires intravenous infusions. For visceral leishmaniasis, prevalent in East Africa, India, and Brazil, invasive diagnostics, long treatment duration (30 days), and drug resistance (up to 65% in India) pose obstacles to control. For Chagas disease, no test of cure exists, and safe, effective drugs have yet to be specifically developed for chronic-stage disease, though over 100 million people in Latin America are at risk.
For the filarial parasitic-worm diseases of onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis), which together infect over 150 million people, the standard treatment of ivermectin, alone or in combination with albendazole, can lead to brain damage or death in people co-infected with loiasis (Loa loa; African eye worm). Moreover, current drugs kill only juvenile and not adult worms, which continue to infect, requiring repeated treatments.
Therefore while continuing to provide existing medicines for NTDs, parallel and greatly enhanced R&D initiatives for new drugs and diagnostics are necessary for disease control or elimination.
Based on DNDi's experience over the past nine years, there are four key elements necessary to support the WHO NTD Roadmap goals by 2020:
Boosting innovation and promoting more open sharing of research knowledge: For instance, today it was announced that 11 pharmaceutical companies have committed to provide access to their compound libraries, including data and knowledge about the compounds, to find potential drug candidates for NTDs. Licensing agreements concluded, for example the agreement announced between DNDi and Abbott, ensure patient access to drugs developed from the collaboration in all endemic countries, regardless of income level.
Forging public and private innovative partnerships for drug development: The collaborations DNDi has established with private partners are essential to developing new treatments. DNDi seeks a balanced mix of partnerships with private and public organizations, including academia, national control programmes, and implementing organizations. Innovative industrial partnerships include Eisai, Sanofi, and Cipla to co-develop new drugs at an affordable price, and a collaboration announced today with Johnson & Johnson, Abbott, and Pfizer to work on a macrofilaricide drug for filarial diseases.
Ensuring endemic-country involvement and leadership to meet patient needs: Strong leadership from governments, including national control programmes, is essential for defining needs and eventually ensuring treatment access for patients, as well as playing a crucial role in conducting research. DNDi works with partners in endemic countries to strengthen regional clinical research networks, which bring together researchers, clinicians, regulatory agencies, national programme managers, and, ideally, patients themselves. These research platforms are vital for ensuring that the R&D process starts and ends with patient needs at the centre.
Attaining sustainable and diversified funding for R&D: DNDi welcomes the financial commitments from DFID (UK), the Bill & Melinda Gates Foundation, and public funders such as Germany, France, the Netherlands, Spain, and Switzerland, yet additional commitments from other major funders, such as the US Agency for International Development (USAID) and governments of emerging economies, must be secured to support accelerated NTD product development. In addition, new R&D incentives, such as prizes, and innovative financing mechanisms, such as a financial transaction tax (FTT) for health, must be supported.
'To make a real difference in the lives of the poorest and most neglected populationsto bring the best science to the most neglected we must go beyond individual success stories and move toward sustainable change, and today's commitments show that we are headed in a right direction', says Dr Pcoul. 'We need both strong coordination of programmes to treat patients today and a new global framework for R&D under the leadership of WHO to ensure R&D priority setting according to needs, secure sustainable financing, and establish an enabling policy environment that guarantees both innovation and access for neglected patients.'
###
About DNDi
The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit research and development organization working to deliver new treatments for neglected diseases, in particular sleeping sickness (human African trypanosomiasis), Chagas disease, leishmaniasis, filarial infections, malaria, and paediatric HIV. DNDi was established in 2003 by Mdecins Sans Frontires/Doctors Without Borders (MSF), Oswaldo Cruz Foundation (FIOCRUZ) from Brazil, Indian Council of Medical Research (ICMR), Kenya Medical Research Institute (KEMRI), Ministry of Health of Malaysia, and Pasteur Institute of France. The WHO Special Programme for Tropical Disease Research (WHO/TDR) serves as a permanent observer. Since 2003, DNDi has delivered six new treatments for neglected patients: two fixed-dose antimalarials (ASAQ and ASMQ), nifurtimox-eflornithine combination therapy (NECT) for late-stage sleeping sickness, sodium stibogluconate and paromomycin (SSG&PM) combination therapy for visceral leishmaniasis in Africa, a set of combination therapies for visceral leishmaniasis in Asia, and a paediatric dosage form of benznidazole for Chagas disease.
DNDi has helped establish three clinical research platforms: Leishmaniasis East Africa Platform (LEAP) in Kenya, Ethiopia, Sudan, and Uganda; HAT Platform based in DRC for sleeping sickness; and Chagas Clinical Research Platform in Latin America. Strong regional networks such as these help strengthen research and treatment-implementation capacity in endemic countries.
DNDi North America, New York (English): Oliver Yun
office: 646-616-8681 / mobile: 646-266-5216 / email: oyun@dndi.org
DNDi, on site, day of event (30 January, London): Samantha Bolton,
mobile: 44-79-72-42-86-33 / email: sbolton@dndi.org
About the London NTD event
The commitments announced by DNDi are a key part of a new, coordinated push by a diverse range of public and private partners to combat 10 Neglected Tropical Diseases (NTDs) by 2020. Today, 13 pharmaceutical companies, the U.S. and U.K. governments, the Bill & Melinda Gates Foundation, the World Bank and officials from NTD-endemic countries pledged to bring a unique focus to defeating these diseases and to work together to improve the lives of the billion people worldwide affected by NTDs.
In the largest coordinated effort to date to combat NTDs, the group announced at an event at the Royal College of Physicians that they would: sustain or expand existing drug donation programs to meet demand through 2020; share expertise and compounds to accelerate research and development of new drugs; and provide more than US$785 million to support R&D efforts and strengthen drug distribution and implementation programmes. The partners also signed onto the "London Declaration on Neglected Tropical Diseases," in which they pledged new levels of collaboration and tracking and reporting of progress.
New funding commitments will fully support work toward the eradication of Guinea worm, as well as expedite progress toward the 2020 goals of: elimination for lymphatic filariasis, blinding trachoma, sleeping sickness and leprosy; and control of soil-transmitted helminthes, schistosomiasis, river blindness, Chagas and visceral leishmaniasis.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Filling R&D gaps key to succeeding in NTD control and elimination goals by 2020Public release date: 30-Jan-2012 [ | E-mail | Share ]
Contact: Violaine Dallenbach vdallenbach@dndi.org 41-794-241-474 Drugs for Neglected Diseases Initiative
Geneva & London On the occasion of today's high-level event in London, 'Uniting to Combat Neglected Tropical Diseases,' organized in support of the new World Health Organization (WHO) Neglected Tropical Disease (NTD) 2020 Roadmap, the Drugs for Neglected Diseases initiative (DNDi) welcomes the commitments from various partners and emphasizes that filling the major gaps in research and development (R&D) for new treatment and diagnostic tools is key to effectively support elimination or control of targeted NTDs by 2020.
Since its inception in 2003, DNDi, a not-for-profit R&D organization, has worked to develop and deliver new drugs for NTDs, in particular those with the highest mortality rates: human African trypanosomiasis (sleeping sickness), Chagas disease, and visceral leishmaniasis (kala azar). DNDi was created to address the market and public-policy failures that had led to a virtual standstill in R&D for new drugs to treat neglected diseases. Working collaboratively with public and private partners worldwide, DNDi has developed six new treatments for neglected patients, with several new drug candidates in the R&D pipeline, including two for sleeping sickness (fexinidazole, oxaborole/SCYX-7158) and one for Chagas (E1224) in clinical trials.
'For some NTDs, especially those with the highest death rates such as sleeping sickness, Chagas disease, and visceral leishmaniasis, disease control or elimination will only be achievable with further commitments to R&D,' says Dr Bernard Pcoul, Executive Director of DNDi. 'New drugs and diagnostics are urgently needed to improve patient care, respond to the challenge of drug resistance, and enhance prospects for achieving disease elimination.'
In the case of sleeping sickness, which continues to kill in remote or unstable pockets of sub-Saharan Africa, diagnostic tools are inadequate (painful lumbar punctures must be performed), and while nifurtimox-eflornithine combination therapy is an improved option therapy, it still requires intravenous infusions. For visceral leishmaniasis, prevalent in East Africa, India, and Brazil, invasive diagnostics, long treatment duration (30 days), and drug resistance (up to 65% in India) pose obstacles to control. For Chagas disease, no test of cure exists, and safe, effective drugs have yet to be specifically developed for chronic-stage disease, though over 100 million people in Latin America are at risk.
For the filarial parasitic-worm diseases of onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis), which together infect over 150 million people, the standard treatment of ivermectin, alone or in combination with albendazole, can lead to brain damage or death in people co-infected with loiasis (Loa loa; African eye worm). Moreover, current drugs kill only juvenile and not adult worms, which continue to infect, requiring repeated treatments.
Therefore while continuing to provide existing medicines for NTDs, parallel and greatly enhanced R&D initiatives for new drugs and diagnostics are necessary for disease control or elimination.
Based on DNDi's experience over the past nine years, there are four key elements necessary to support the WHO NTD Roadmap goals by 2020:
Boosting innovation and promoting more open sharing of research knowledge: For instance, today it was announced that 11 pharmaceutical companies have committed to provide access to their compound libraries, including data and knowledge about the compounds, to find potential drug candidates for NTDs. Licensing agreements concluded, for example the agreement announced between DNDi and Abbott, ensure patient access to drugs developed from the collaboration in all endemic countries, regardless of income level.
Forging public and private innovative partnerships for drug development: The collaborations DNDi has established with private partners are essential to developing new treatments. DNDi seeks a balanced mix of partnerships with private and public organizations, including academia, national control programmes, and implementing organizations. Innovative industrial partnerships include Eisai, Sanofi, and Cipla to co-develop new drugs at an affordable price, and a collaboration announced today with Johnson & Johnson, Abbott, and Pfizer to work on a macrofilaricide drug for filarial diseases.
Ensuring endemic-country involvement and leadership to meet patient needs: Strong leadership from governments, including national control programmes, is essential for defining needs and eventually ensuring treatment access for patients, as well as playing a crucial role in conducting research. DNDi works with partners in endemic countries to strengthen regional clinical research networks, which bring together researchers, clinicians, regulatory agencies, national programme managers, and, ideally, patients themselves. These research platforms are vital for ensuring that the R&D process starts and ends with patient needs at the centre.
Attaining sustainable and diversified funding for R&D: DNDi welcomes the financial commitments from DFID (UK), the Bill & Melinda Gates Foundation, and public funders such as Germany, France, the Netherlands, Spain, and Switzerland, yet additional commitments from other major funders, such as the US Agency for International Development (USAID) and governments of emerging economies, must be secured to support accelerated NTD product development. In addition, new R&D incentives, such as prizes, and innovative financing mechanisms, such as a financial transaction tax (FTT) for health, must be supported.
'To make a real difference in the lives of the poorest and most neglected populationsto bring the best science to the most neglected we must go beyond individual success stories and move toward sustainable change, and today's commitments show that we are headed in a right direction', says Dr Pcoul. 'We need both strong coordination of programmes to treat patients today and a new global framework for R&D under the leadership of WHO to ensure R&D priority setting according to needs, secure sustainable financing, and establish an enabling policy environment that guarantees both innovation and access for neglected patients.'
###
About DNDi
The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit research and development organization working to deliver new treatments for neglected diseases, in particular sleeping sickness (human African trypanosomiasis), Chagas disease, leishmaniasis, filarial infections, malaria, and paediatric HIV. DNDi was established in 2003 by Mdecins Sans Frontires/Doctors Without Borders (MSF), Oswaldo Cruz Foundation (FIOCRUZ) from Brazil, Indian Council of Medical Research (ICMR), Kenya Medical Research Institute (KEMRI), Ministry of Health of Malaysia, and Pasteur Institute of France. The WHO Special Programme for Tropical Disease Research (WHO/TDR) serves as a permanent observer. Since 2003, DNDi has delivered six new treatments for neglected patients: two fixed-dose antimalarials (ASAQ and ASMQ), nifurtimox-eflornithine combination therapy (NECT) for late-stage sleeping sickness, sodium stibogluconate and paromomycin (SSG&PM) combination therapy for visceral leishmaniasis in Africa, a set of combination therapies for visceral leishmaniasis in Asia, and a paediatric dosage form of benznidazole for Chagas disease.
DNDi has helped establish three clinical research platforms: Leishmaniasis East Africa Platform (LEAP) in Kenya, Ethiopia, Sudan, and Uganda; HAT Platform based in DRC for sleeping sickness; and Chagas Clinical Research Platform in Latin America. Strong regional networks such as these help strengthen research and treatment-implementation capacity in endemic countries.
DNDi North America, New York (English): Oliver Yun
office: 646-616-8681 / mobile: 646-266-5216 / email: oyun@dndi.org
DNDi, on site, day of event (30 January, London): Samantha Bolton,
mobile: 44-79-72-42-86-33 / email: sbolton@dndi.org
About the London NTD event
The commitments announced by DNDi are a key part of a new, coordinated push by a diverse range of public and private partners to combat 10 Neglected Tropical Diseases (NTDs) by 2020. Today, 13 pharmaceutical companies, the U.S. and U.K. governments, the Bill & Melinda Gates Foundation, the World Bank and officials from NTD-endemic countries pledged to bring a unique focus to defeating these diseases and to work together to improve the lives of the billion people worldwide affected by NTDs.
In the largest coordinated effort to date to combat NTDs, the group announced at an event at the Royal College of Physicians that they would: sustain or expand existing drug donation programs to meet demand through 2020; share expertise and compounds to accelerate research and development of new drugs; and provide more than US$785 million to support R&D efforts and strengthen drug distribution and implementation programmes. The partners also signed onto the "London Declaration on Neglected Tropical Diseases," in which they pledged new levels of collaboration and tracking and reporting of progress.
New funding commitments will fully support work toward the eradication of Guinea worm, as well as expedite progress toward the 2020 goals of: elimination for lymphatic filariasis, blinding trachoma, sleeping sickness and leprosy; and control of soil-transmitted helminthes, schistosomiasis, river blindness, Chagas and visceral leishmaniasis.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
After months of trying to ameliorate a disease ravaging the GOP, Jon Huntsman Jr. has moved into fighting cancers that afflict human beings rather than the body politic by taking over as chairman of a foundation that funds his family?s Institute, a research, education and treatment center with a full-time faculty and staff of 1300.
In his political hiatus, Huntsman worked hard but failed to offer Republicans the radical surgery that might have saved it from the coma in which it now seems to be sunk. Let?s hope he encourages scientists to be more aggressive in the labs.
In the Weekly Address today, the President reminds us again of how far the Tea Party virus has progressed by citing the case of Sen. Mike Lee, who unseated long-time conservative Robert Bennett last year:
?Just two days ago, a senator from Utah promised to obstruct every single American I appoint to a judgeship or public service position-- unless I fire the consumer watchdog I put in place to protect the American people from financial schemes or malpractice.
?For the most part, it?s not that this senator thinks these nominees are unqualified. In fact, all of the judicial nominees being blocked have bipartisan support. And almost 90 percent have unanimous support from the Judiciary Committee.
?Instead, one of his aides told reporters that the senator plans to, and I?m quoting here, ?Delay and slow the process in order to get the President?s attention.?
?One senator gumming up the works for the whole country is certainly not what our founding fathers envisioned.?
This particular pustule will be on the Senate?s backside for five more years but, in November, voters can start surgically removing some of the others.
Good luck to Huntsman in his quest for cancer cures. We are going to have find our own.
Tiny bubbles float algae to the water's surface for harvest and processing. Sophie Bushwick reports.
January 27, 2012
More 60-Second Science
Subscribe via iTunes
Algae naturally produce oil. When it?s processed, that oil can be turned into biofuel, an alternative energy source. There?s just one snag?harvesting the oil from algae-filled water is prohibitively expensive. But researchers have come up with an effervescent solution: bubbles smaller than the width of a human hair can help reduce the costs of collecting algae oil.
So-called microbubbles are already used for water purification?they surround contaminants and float them out of the liquid. Similarly, in water containing algae, bubbles can float the algae to the surface for easy collection and processing.
The research builds on previous work that used microbubbles to grow algae more densely and thus increase production. This time, however, the researchers produced the fizziness with a new method that uses far less energy, and is cheaper to install. The study is in the journal Biotechnology and Bioengineering. [James Hanotu, HC Hemaka Bandulasena and William B Zimmerman, Microflotation performance for algal separation]
Although microbubbles improve algae harvesting in the lab, they still have to work at larger scales. The researchers are planning a pilot program for an algae biofuel plant, in the hope of making really green energy.
?Sophie Bushwick
[The above text is a transcript of this podcast]???
?
Facebook CEO Mark Zuckerberg could be worth $20 billion if current estimates hold true.
By msnbc.com staff and wire
Updated at 5:25 p.m. ET
Facebook is poised to file papers as early as next week for an initial public offering that could be one of the biggest in history, creating hundreds if not thousands of instant millionaires, The Wall Street Journal reported Friday.
The highly anticipated IPO will value the world's largest social networking site?at between $75 billion and $100 billion, the Journal reported on its website. So far the Journal appears to be alone with the report. Facebook declined to comment.
Founded in a Harvard dorm room in 2004 by Mark Zuckerberg and his friends, Facebook has grown into the world's biggest social network with over 800 million members. Facebook earned roughly $1.5 billion in operating profits on $3.8 billion in revenues last year, CNBC's Julia Boorstin reported, citing unidentified sources.
The impending IPO -- expected to raise $10 billion -- is a prized trophy for investment banks, setting up a fierce competition on Wall Street, particularly between Morgan Stanley and Goldman Sachs, which are expected to be the two lead underwriters.
The IPO could come about three to four months after the filing, which likely would put it sometime in May. Facebook is under legal pressure to go public this year because of the so-called ?500 shareholder rule,? which requires companies to disclose financial information by the end of the first quarter the year after the company tops 500 shareholders.
Information about Facebook's ownership structure and employee compensation packages is hard to come by, since the still-private company discloses very little. But that could all change next week if the company files documents required by the Securities and Exchange Commission to offer stock to the public.
It is clear that Facebook's earliest employees, who were given ownership stakes, and early venture capital investors -- such as Accel Partners, Greylock Partners and Paypal co-founder Peter Thiel -- will see the biggest paydays.
The Journal reported that Accel could see a return of $9 billion on an initial investment of $12.7 million. Several other venture capital firms would see their stakes grow to over $1 billion in value. Thiel's current stake could not be determined.
Zuckerberg, 27, is estimated to own a little over a fifth of the company, according to "The Facebook Effect" author David Kirkpatrick, meaning he could be worth $20 billion. The latest Forbes 400 list estimated Zuckerberg was worth $17.5 billion, making him No. 14 on its list of richest Americans.
The wealth will trickle down to engineers, salespeople and other staffers who later joined the company, since most employees receive salary plus some kind of equity-based compensation, such as restricted stock units or stock options.
Facebook's headcount has swelled from 700 employees in late 2008 to more than 3,000 today. Given its generous use of equity-based compensation in past years, people familiar with Facebook say that even by conservative estimates there are likely to be well over?1,000?people who will become instant millionaires, at least on paper,?when the company goes public.
"There will be thousands of millionaires," said a former in-house recruiter at Facebook, who did not want to be identified because of confidentiality agreements.
Would you buy Facebook stock? Vote below and then?share on your thoughts on -- where else? -- Facebook.
Nearly 12,000 people will die of head and neck cancer in the United States this year and worldwide cases will exceed half a million.
A study published this week in the journal Carcinogenesis shows that in both cell lines and mouse models, grape seed extract (GSE) kills head and neck squamous cell carcinoma cells, while leaving healthy cells unharmed.
?It?s a rather dramatic effect,? says Rajesh Agarwal, PhD, investigator at the University of Colorado Cancer Center and professor at the Skaggs School of Pharmaceutical Sciences.
It depends in large part, says Agarwal, on a healthy cell?s ability to wait out damage.
?Cancer cells are fast-growing cells,? Agarwal says. ?Not only that, but they are necessarily fast growing. When conditions exist in which they can?t grow, they die.?
Grape seed extract creates these conditions that are unfavorable to growth. Specifically, the paper shows that grape seed extract both damages cancer cells DNA (via increased reactive oxygen species) and stops the pathways that allow repair (as seen by decreased levels of the DNA repair molecules Brca1 and Rad51 and DNA repair foci).
?Yet we saw absolutely no toxicity to the mice, themselves,? Agarwal says.
Again, the grape seed extract killed the cancer cells but not the healthy cells.
Related:
Whole Grape ? Seed and Skin ? May Be Perfect Colon Cancer Fighting Food
LONDON ? The Museum of London is displaying a coin found by the River Thames that may have been used nearly 2,000 years ago as a "brothel token" in Roman London.
The bronze coin shows a man and woman in an intimate embrace.
Senior curator Caroline McDonald said Thursday it is impossible to determine precisely what the coin was used for.
She says it is probable brothels existed in London when the coin was in circulation after the Roman invasion of Britain in the 1st Century A.D.
Experts believe the coin was concealed by mud along the river banks for some 2,000 years before it was discovered recently by a man with a metal detector looking for objects near Putney Bridge.
WASHINGTON (Reuters) ? New single-family home sales unexpectedly fell in December for the first time in four months and the median home price dropped, dampening some of the hopes the housing sector will boost the economy this year.
The Commerce Department said on Thursday sales decreased 2.2 percent to a seasonally adjusted 307,000-unit annual rate.
Economists polled by Reuters had forecast sales at a 320,000-unit rate. November's sales pace was revised slightly lower.
The housing market remains constrained by high unemployment, falling prices and an oversupply of unsold homes following a bust that triggered the 2007-09 recession.
Sales fell in two of the country's four regions, including a 10.1 percent drop in the South, where most new homes were sold.
The median sales price for a new home fell 2.5 percent to $210,300 last month, the biggest drop in four months. Compared to December last year, the median price was down 12.8 percent.
There were a record low 157,000 new homes on the market last month and at December's sales pace, it would take 6.1 months to clear them, up from 6.0 months in November.
For all of 2011, sales were down 6.2 percent from the prior year, with 302,000 new single-family homes being sold.
(Reporting by Jason Lange; Editing by Andrea Ricci)
Sparxgear has designed a Fire Piston, and they are using Kickstarter for funding.? Never heard of a fire piston?? Before the days of matches, fires were often started with a fire piston.? A combustible material – cloth, wood, even milkweek down, etc. – is inserted on the end of? the fire piston.? Quick compression of [...]
ScienceDaily (Jan. 25, 2012) ? Eight years after landing on Mars for what was planned as a three-month mission, NASA's enduring Mars Exploration Rover Opportunity is working on what essentially became a new mission five months ago.
Opportunity reached a multi-year driving destination, Endeavour Crater, in August 2011. At Endeavour's rim, it has gained access to geological deposits from an earlier period of Martian history than anything it examined during its first seven years. It also has begun an investigation of the planet's deep interior that takes advantage of staying in one place for the Martian winter.
Opportunity landed in Eagle Crater on Mars on Jan. 25, 2004, Universal Time and EST (Jan. 24, PST), three weeks after its rover twin, Spirit, landed halfway around the planet. In backyard-size Eagle Crater, Opportunity found evidence of an ancient wet environment. The mission met all its goals within the originally planned span of three months. During most of the next four years, it explored successively larger and deeper craters, adding evidence about wet and dry periods from the same era as the Eagle Crater deposits.
In mid-2008, researchers drove Opportunity out of Victoria Crater, half a mile (800 meters) in diameter, and set course for Endeavour Crater, 14 miles (22 kilometers) in diameter.
"Endeavour is a window further into Mars' past," said Mars Exploration Rover Program Manager John Callas, of NASA's Jet Propulsion Laboratory, Pasadena, Calif.
The trek took three years. In a push to finish it, Opportunity drove farther during its eighth year on Mars -- 4.8 miles (7.7 kilometers) -- than in any prior year, bringing its total driving distance to 21.4 miles (34.4 kilometers).
The "Cape York" segment of Endeavour's rim, where Opportunity has been working since August 2011, has already validated the choice of Endeavour as a long-term goal. "It's like starting a new mission, and we hit pay dirt right out of the gate," Callas said.
The first outcrop that Opportunity examined on Cape York differs from any the rover had seen previously. Its high zinc content suggests effects of water. Weeks later, at the edge of Cape York, a bright mineral vein identified as hydrated calcium sulfate provided what the mission's principal investigator, Steve Squyres of Cornell University, Ithaca, N.Y., calls "the clearest evidence for liquid water on Mars that we have found in our eight years on the planet."
Mars years last nearly twice as long as Earth years. Entering its ninth Earth year on Mars, Opportunity is also heading into its fifth Martian winter. Its solar panels have accumulated so much dust since Martian winds last cleaned them -- more than in previous winters -- the rover needs to stay on a sun-facing slope to have enough energy to keep active through the winter.
The rover team has not had to use this strategy with Opportunity in past winters, though it did so with Spirit, farther from the equator, for the three Martian winters that Spirit survived. By the beginning of the rovers' fourth Martian winter, drive motors in two of Spirit's six wheels had ceased working, long past their design lifespan. The impaired mobility kept the rover from maneuvering to an energy-favorable slope. Spirit stopped communicating in March 2010.
All six of Opportunity's wheels are still useful for driving, but the rover will stay on an outcrop called "Greeley Haven" until mid-2012 to take advantage of the outcrop's favorable slope and targets of scientific interest during the Martian winter. After the winter, or earlier if wind cleans dust off the solar panels, researchers plan to drive Opportunity in search of clay minerals that a Mars orbiter's observations indicate lie on Endeavour's rim.
"The top priority at Greeley Haven is the radio-science campaign to provide information about Mars' interior," said JPL's Diana Blaney, deputy project scientist for the mission. This study uses weeks of tracking radio signals from the stationary rover to measure wobble in the planet's rotation. The amount of wobble is an indicator of whether the core of the planet is molten, similar to the way spinning an egg can be used to determine whether it is raw or hard-boiled.
Other research at Greeley Haven includes long-term data gathering to investigate mineral ingredients of the outcrop with spectrometers on Opportunity's arm, and repeated observations to monitor wind-caused changes at various scales.
The Moessbauer spectrometer, which identifies iron-containing minerals, uses radiation from cobalt-57 in the instrument to elicit a response from molecules in the rock. The half-life of cobalt-57 is only about nine months, so this source has diminished greatly. A measurement that could have been made in less than an hour during the rover's first year now requires weeks of holding the spectrometer on the target.
Observations for the campaign to monitor wind-caused changes range in scale from dunes in the distance to individual grains seen with the rover's microscopic imager. "Wind is the most active process on Mars today," Blaney said. "It is harder to watch for changes when the rover is driving every day. We are taking advantage of staying at one place for a while."
NASA's Jet Propulsion Laboratory, a division of the California Institute of Technology in Pasadena, manages the Mars Exploration Rover Project for the NASA Science Mission Directorate, Washington. More information about Opportunity is online at: http://www.nasa.gov/rovers and http://marsrovers.jpl.nasa.gov . You can follow the project on Twitter at http://twitter.com/MarsRovers and on Facebook at http://www.facebook.com/marsrovers .
Recommend this story on Facebook, Twitter, and Google +1:
Other bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by NASA/Jet Propulsion Laboratory.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Note: If no author is given, the source is cited instead.
Disclaimer: Views expressed in this article do not necessarily reflect those of ScienceDaily or its staff.
NEW YORK (Reuters) ? Capital markets in 2012 are better than they were in 2011, Morgan Stanley Chief Executive James Gorman said on Wednesday, adding that his bank is in a "very good position for Basel III standards."
Gorman, speaking to CNBC from Davos, Switzerland, said confidence will rise after euro zone stability improves, while stressing that Morgan Stanley (MS.N) is in a very solid position. "If you had all sovereigns, all corporates and all financial institutions blow up in Europe at the same time, Morgan Stanley would still be fine," he said.
Gorman also said Morgan Stanley would not need to raise capital in the near term. Morgan Stanley's capital levels have been a concern for investors because it will need to comply with new, stricter rules set by the Basel Committee and U.S. regulators.
The Basel III accord, agreed to by the Basel Committee, an international group of regulators, will require banks to hold at least 7 percent of core Tier 1 capital in the form of retained earnings or pure equity.
There are also concerns because Morgan Stanley may need a big chunk of cash to purchase the next stake of its Morgan Stanley Smith Barney venture from Citigroup Inc (C.N).
Morgan Stanley currently owns 51 percent of the wealth management business and has the option to buy another 14 percent in May at fair market value. Gorman reiterated his commitment to buy the business on Wednesday, a purchase he said will take a priority over stock buybacks or dividends in the near-term.
(Reporting by Sam Forgione and Lauren LaCapra; Editing by Leslie Adler)
Republican presidential candidate, former Pennsylvania Sen. Rick Santorum speaksat PGT Industries in North Venice, Fla., Monday, Jan. 23, 2012. (AP Photo/Paul Sancya)
Republican presidential candidate, former Pennsylvania Sen. Rick Santorum speaksat PGT Industries in North Venice, Fla., Monday, Jan. 23, 2012. (AP Photo/Paul Sancya)
Republican presidential candidate, former Pennsylvania Sen. Rick Santorum, speaks at PGT Industries in North Venice, Fla., Monday, Jan. 23, 2012. (AP Photo/Paul Sancya)
Republican presidential candidate, former Pennsylvania Sen. Rick Santorum, arrives at PGT Industries in North Venice, Fla., Monday, Jan. 23, 2012. (AP Photo/Paul Sancya)
LADY LAKE, Fla. (AP) ? Republican presidential candidate Rick Santorum on Monday warned Florida's seniors that the Democrats' health law would limit their access to doctors and dollars and criticized his main rivals for backing its requirement that younger Americans buy health insurance.
Santorum tried to draw a connection between Medicare and a key provision of the health care law, the so-called individual mandate, which doesn't affect older Americans because virtually all of them are already covered through the government program.
Santorum, however, argues that the health care law puts a cap on Medicare spending and that, because Mitt Romney and Newt Gingrich at one time supported the idea of an individual mandate, they share the blame for the impact of the health care law on Medicare.
The former Pennsylvania senator said Republicans cannot pick a nominee who would not be able to challenge President Barack Obama aggressively on the law its opponents call "Obamacare."
"I never supported anything close to Obamacare. Sadly, that is not the case with the rest of the people in this field," Santorum told an older audience at an American Legion hall near Orlando. "Whether it's Gov. Romney with Romneycare or Speaker Gingrich and a 20-year promotion of the individual mandate."
Both candidates, he said, should be unacceptable to conservatives, especially among seniors who make up much of Florida. Some 3.3 million Floridians are over the age of 65.
Santorum centered his criticism of the health care law on a panel that is intended to keep increases in Medicare spending manageable by controlling payments to health care providers. The Independent Payment Advisory Board's unelected members would have too much power over seniors' care, he said.
The panel was designed to curb Medicare spending and its recommendations ? such as cutting Medicare rates paid to doctors ? would be binding unless Congress overrules them. Santorum called it a clever way for Obama to avoid taking responsibility for cuts.
"The effect is rationing care. It's rationing indirectly. You'll be mad at your doctor, you'll be mad at your hospital," he said. "You won't be mad at Obama, who is the real reason for your doctor or hospital not seeing you."
But the panel has yet to be set up, and Obama's health care law explicitly forbids it from rationing care, shifting costs to retirees, restricting benefits or raising the Medicare eligibility age.
It's terrible policy, Santorum said.
"The bottom line is more and more providers of health care are not taking Medicare because of the reimbursement rates," he added.
And when people do see a doctor, it is after delay, Santorum said.
"The average wait is getting longer and longer," he said. "The average wait is 29 days now."
However, a nonpartisan agency that advises Congress on Medicare policy, reports that access for seniors generally remains good, despite localized problems and concerns about appointments for primary care.
The Medicare Payment Advisory Commission said in a report to lawmakers last year that its most recent survey showed beneficiaries reported "similar or better access" than people age 50 to 64 with private insurance.
Image by Lennon Day-Reynolds, taken at the California Academy of Sciences for the Love Life 2012 photo competition (used under a CC-BY-NC 2.0 license)
One of my favorite institutions, the California Academy of Sciences in San Francisco, is holding a photography competition:
The Love Life photo competition returns for a second year with two new categories and many more prizes! Submit your loveliest photos of the California Academy of Sciences and the natural world for judging by top photo experts. Then vote for your favorite photos online to be entered in the People?s Choice Award. All winners will be announced at the March 1st Nightlife.
Most categories require photographs captured at the museum itself. One- for photography that encourages awareness of, or action for, the natural world- accepts submissions from anywhere.
The contest allows photographers to retain copyright, and the deadline is February 1st.
Love Life 2012 Competition
image source
About the Author: Alex Wild is an Illinois-based entomologist who studies the evolutionary history of ants. In 2003 he founded a photography business as an aesthetic complement to his scientific work, and his natural history photographs appear in numerous museums, books, and media outlets. Follow on Twitter @myrmecos.
More??
The views expressed are those of the author and are not necessarily those of Scientific American.
In case you forgot, both Pantech's new dual-core smartphone and waterproof tablet have arrived and Ma Bell's bundled the pair together to form some kind of middleweight Android tag-team. The price of a matching tablet and smartphone? Expect to pay $250 on contract, and you'll need plans for both the Element and Burst. Those feeling flush can grab the full details at the source.
As the strange case of file-sharing site Megaupload continues to unfold, many wonder if the federal government will begin to clamp down on similar sites that function like Megaupload, with easy sharing and hosting of copyrighted files.
Already, two well-known file-sharing services, Uploaded.to and Filesonic have disabled several features of their sites this weekend because of the Megaupload scandal. Others are sure to follow.
But Derek Labian, CEO of popular cloud-based file-hosting site MediaFire, told VentureBeat in an interview today that he isn?t too concerned about the government going after his company because, unlike Megaupload, MediaFire doesn?t incentivize piracy.
?We don?t have a business built on copyright infringement.? Labain said. ?Like many other cloud-based sharing services like Box.net and Dropbox, we?re a legitimate business targeting professionals.?
When it comes to Megaupload, Labian described Kim Dotcom and his organization as ?shady? and said the $175 million in revenues the company made should give people pause. He noted that Megaupload?s structure gave users monetary rewards for uploading pirated content. Users of the service could upload without a cap but users who want to download a large file (or download it faster) would have to pay for it. Those who uploaded the best files would be given free account upgrades or even cash.
?Megaupload was making a ridiculous amount of money with a ridiculously bad service,? Labian said. ?We frankly don?t see ourselves in the same space.?
A little more background on MediaFire: The privately funded company out of Woodlands, Tex. was founded in 2006 and has steadily offered better ways to host and share large files. Because it offers an incredibly easy to way to share 200MB files for free with other people, the company has attracted employees at 86 percent of the Fortune 500 for sending files that are too large for e-mail. It offers unlimited downloads and file storage, and if you want to upload larger files with long-term storage, you can pay $9 a month for a Pro account or $49 a month for a Business account.
But the company?s free file-sharing solution can also be used easily for sharing copyrighted files, especially music, with friends, relatives or anyone on the web. A Google search for a song name, an artist name and ?MediaFire,? for example, will likely bring you to a copy of that file that can easily be downloaded from a MediaFire page.
When asked about the Googling issue, Labian said that MediaFire is a ?private service? and the only reason Google indexes a MediaFire page is when it has been shared by a user on a third-party site. He said MediaFire isn?t at fault for this and said Google should look into the issue.
?We try to steer clear of things that would attract scrutiny,? Labian said. ?If people are pirating on our service, we don?t want those people to use it.?
Another reason Labian said he wasn?t worried about the government stepping in is because the company maintains a ?good relationship? with various government bodies, including ?Homeland Security, ICE, and the FBI.? Following DMCA protocols, whenever MediaFire is notified of a copyrighted file being shared inappropriately, the company immediately takes it down.
As for the future, MediaFire is optimistic about what?s to come. Labian said the company has been working for a year on its next set of products, which will emphasize collaboration and focus on business users. He teased what was coming by saying that cloud storage providers Box.net and Dropbox significantly disrupted the cloud storage space, but MediaFire would do it next.
?This is a tough market to be in, but we?re constantly looking to innovate,? Labian said. ?Sharing will always be important, but it?s not the only important aspect for our customers.?
Next Story: RIM co-CEOs will step down Monday?what took them so?long? Previous Story: Ex-con looking to fund over 15,000 inventions designed while incarcerated?(exclusive)
??Getting rid of full-fat dairy products and replacing them with low-fat or fat-free choices saves you major calories, not to mention a whole lot of unhealthy saturated fat. Click for more and to join Joy Bauer's 25,000 pound Weight-Loss Challenge!
We saw plenty of the Xperia S before it officially surfaced at CES, and we've already seen leaked photos of the MT27i "Pepper", along with a purported leaked roadmap for other Sony phones. Today, though, XperiaBlog has the first image of at what is reportedly the Sony (Ericsson) ST25i "Kumquat", a mid to high-end Android phone with a 3.5-inch display and a familiar industrial design.
The "Kumquat", which according to the leaked roadmap is due this April at a ~€260 price point, is apparently powered by a 1GHz dual-core processor, with a 5MP camera and a qHD (960x540) display. If the rumored specs and price are correct -- and admittedly that's still a pretty big "if" -- this device could be very tempting for those looking for a smaller, more portable smartphone with high-end specs.
Hopefully we'll see more of the "Kumquat" at Sony's Mobile World Congress presentation in just a few weeks, where the manufacturer looks set to reveal more of its 2012 line-up.
Screen grab from youtube video showing the arrest of Occupy LA activist Sergio Ballesteros on Thursday, Jan. 12. Ballesteros, 30, was released on $50,000 bail early Tuesday. He is charged with "lynching"--a felony charge originally drafted to deal with vigilante mobs.
By Kari Huus, msnbc.com
Sergio Ballesteros, 30, has been involved in Occupy LA since the movement had its California launch in October. But this week, his activism took an abrupt turn when?he was arrested on a felony charge ? lynching.
Under the California penal code, lynching is ?taking by means of a riot of any person from the lawful custody of any peace officer," where "riot" is defined as two or more people threatening violence or disturbing the peace. The original purpose of the legal code section 405(a)?was to protect defendants in police custody from vigilante mobs ? especially black defendants from racist groups.
Whether the police allegation in this case will be pursued by by California?s courts is uncertain. But the felony charge ? which carries a potential?four-year prison sentence ? is the kind of accusation that can change the landscape for would-be demonstrators.
Occupy protesters bring their discontent to Congress
"Felonies really heighten the stakes for the protesters," said Baher Azmy, legal director at Center for Constitutional Rights in New York. "I think in situations where there are mass demonstrations and a confrontation between protesters and police, one always has to be on the lookout for exaggerated interpretations of legal rules that attempt to punish or squelch the protesters."
Ballesteros, a teacher-turned-social-activist,?was one of two people arrested during an "art walk" in downtown Los Angeles on Thursday. He and other Occupy LA activists ? maybe 200, he said ? had joined the procession to bring their message about social injustice to the thousands of gallery-goers.
Adam Alders, a protester who was playing a drum was arrested after stepping off the curb into the street.?Ballesteros said that in doing so, the drummer was joining hundreds of other people who could not fit on the crowded sidewalk.
Occupy protesters underwhelmed by senator's staff
Ballesteros said he was across the street when he saw the arrest ? which he said looked excessively rough -- and it was ?startling.? Under legal advice, Ballesteros is not providing additional detail, but apparently he objected ? in some fashion ? to the arrest. A video of the crowded scene posted on YouTube?shows Ballesteros on the ground, being handcuffed.
The police report says officers called for backup when Ballesteros pulled Alders out into the crowd, which was "hostile."
A video of the event shows the crowd chanting "let him go!"
He was booked into jail on a felony charge, the Los Angeles Police department confirmed, and released on $50,000 bail early Tuesday morning.
'I can't go out and express myself' Ballesteros is not the first protester to face this 1933 California law.
Occupy Oakland activist Tiffany Tran, 23, was arrested?Dec. 30 and charged with "lynching." At an arraignment four days later,? prosecutors opted not to file the charges,?the San Francisco Bay Guardian reported. They could change their minds until the one-year statute of limitations expires.
"Now I feel I can?t go out and express myself as I should be able to," Tran told the paper.
Houston DA turns up the heat on Occupy activists?
In the handful of protest cases in which lynching has been used as a charge?in the past, it later has been dropped. However, in one case, a court concluded that ?lynching? could include ?a person who takes part in a riot leading to his escape from custody."
Many states have laws against lynching ? largely drafted to prevent white supremacists and other vigilante groups from using violence against African Americans?and?white people who supported them. Hundreds of lynchings of this sort took place in the late 1800s through the mid-1900s.
Ballesteros' lawyer?said?use of this?law was perhaps less appealing to the District Attorney than to the police.
Ballesteros is an activist?outside the Occupy movement -- building homes through Habitat for Humanity during his spring breaks, aiding at a children's camp for the poorest kids in the Appalachians during the summer, and acting as mentor for kids in the Los Angeles area.
"Whether the District Attorney has the stomach to charge this model young man with a felony is questionable," saidd Mieka ter Poorten, an LA criminal defense attorney who is handling this case pro bono.
Trying to silence? Ballesteros, who?spoke to msnbc.com on Tuesday, said that he does not believe he will be convicted of lynching.
?They don?t have much,? he said of the case against him.
Ballesteros lawyer, Meika ter Poorten, who is working pro bono on the case, says
He also faces a misdemeanor charge for his arrest?Nov. 30, when he was among more than 200 people who defied eviction from an encampment on the grounds of Los Angeles' City Hall. There was an arraignment for protesters arrested that day, but they were told no charges yet had been filed.
?They have a year to do so,? said Ballesteros. "Now they certainly will. It?s obvious. It?s all political.?
Ballesteros took part in a live video forum between Occupy movement activists and Tea Party activists just a day before his arrest. Click here to hear the discussion.
LAGOS, Nigeria (AP) ? An offshore rig exploring possible oil and gas fields off Nigeria's coast for Chevron Corp. caught fire Monday, and the oil company said officials were still trying to account for all those working there.
Chevron said two workers were missing and 152 others found, but gave no further detail on the missing persons.
The company said it was still investigating the fire, which occurred near its North Apoi oil platform, and which forced it to shut down.
"We immediately flew out people to the nearby North Apoi platform, and have been helping those needing any medical assistance," Chevron spokesman Scott Walker said in a statement.
Chevron did not immediately say what caused the fire. However, Nigeria's government believes a "gas kick" ? a major build up of gas pressure from drilling ? was responsible, said Levi Ajuonoma, a spokesman for the state-run Nigerian National Petroleum Corp.
Chevron and other foreign oil companies in Nigeria pump crude oil in partnership with the state-run company.
Nnimmo Bassey, who runs an environmental watchdog group in Nigeria, said he had received reports from locals nearby that the fire was an industrial incident.
"Workers were trying to contain the gas pressure and they didn't succeed," Bassey said.
The rig is run on Chevron's behalf by contractor FODE Drilling Co., Walker said. Officials with FODE, which has offices in London and Jenkintown, Pennsylvania, could not be immediately reached for comment Monday.
Nigeria is the fifth-largest crude oil exporter to the U.S. It produces about 2.4 million barrels of crude oil a day. However, more than 50 years of oil production has seen environmental damage through delta's maze of muddy creeks and mangroves.
Chevron, based in San Ramon, California, produced an average of 524,000 barrels of crude oil a day from Nigeria in 2010. The company has exploration rights to about 2.2 million acres across Nigeria's delta and offshore.
In a sign of the times, cars are being driven an average of 10.8 years according to automotive market research firm R.L. Polk & Co. That?s a record high, up from 10.4 years in 2010. NBC?s Brian Williams reports.
One of the largest and most well established component companies in the world is seeking a Senior VP Technical Services to lead their global Quality and Engineering strategy. The Senior VP Technical Services will be the prime coordination point for the on-going creation and governance of QHS&E roadmaps for all the major clients, predominantly within Automotive, Truck and Industrial manufacturers.
COMPANY PROFILE: Our client is a Fortune 500 company and a multinational provider of big ticket distribution, supply chain, logistic solutions for component supply into major Automotive Manufacturing, Industrial OEM?s worldwide. They provide their clients with a full vendor rationalisation, stock holding reduction solution through just-in-time supply, inventory management, and streamlined delivery with full product validation and quality ownership. Their client base is a ?who?s who? of O.E.M.?s across automotive (O.E.M. and tier 1), whitegoods, medical equipment, amongst many others.
JOB SPECIFICATION: Senior VP Technical Services or Technical Director of Quality With a team of 220 staff globally (10 direct reports), you will lead from the front and play a key pivotal role liaising with the major global customers regarding QHS&E compliance. 60% of your time will be in the UK, 40% overseas with frequent travel to the USA, China and Europe.
Duties will include ? Participate as a member of the Senior Management Team in formulating corporate strategies, policies, plans and budgets, including the interpretation of and implementation of these strategies and policies into working practise and single Global procedures. ? Monitoring the Company's performance to ensure that the corporate Mission and targets are achieved. ? The successful implementation and full maintenance of defined minimum operating disciplines at all c70 Global locations. ? The standardisation of all Divisional laboratory processes and procedures to 'best practise' and the achievement of Global laboratory accreditations as required. ? The development of comprehensive integrated documented management system (QHS&E), accessible to all personnel. ? To achieve and maintain third party and applicable customer accreditations as required by the Business. ? To build internal, external and third party supplier relationships to ensure full commitment and support.
REQUIREMENTS: Technical Director within an Automotive biased Manufacturing or First Tier environment.
You will have an Engineering degree or equivalent and a proven and consistent track record within a Senior Technical, Quality or Operational role supplying the automotive sector or industrial and engineering O.E.M. markets.
You must have experience in high volume component supply on a just-in-time basis and associated supply chain, logistics and distribution issues and fully conversant with Automotive Quality systems including ISO9001, 14001, TS 16949, and VDA6.2.